Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

October 29, 2022

https://www.globenewswire.com/news-release/2022/10/28/2544156/0/en/Akari-Therapeutics-Announces-Receipt-of-Nasdaq-Minimum-Bid-Price-Notification.html

NEW YORK and LONDON, Oct. 28, 2022 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Akari received a letter from Nasdaq Listing Qualifications indicating that Akari is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.

Read more at globenewswire.com

Related news for (AKTX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.